ReviewFrontiers in bioengineering and biotechnology2025
A comparative study on the governance approaches for biotechnological risks.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The governance approaches for biotechnological risks mainly include the laissez-faire approach, which emphasizes "technology first" but suffers from lagging governance; the preventive approach, which emphasizes "safety first" and uses quantitative risk-benefit analysis as the main method in a single dimension; and the precautionary approach, which also emphasizes "safety first" but has three dimensions of cognition, procedure, and action, and is characterized by forward-looking and proportionality. Emerging biotechnologies are developing rapidly while being filled with a large amount of uncertainty, which increases the complexity of potential biotechnological risks. The precautionary approach, which emphasizes cultivating a cautious awareness and future responsibility in cognition, reversing the burden of proof in procedure, and ensuring that the level of precautionary measures is proportionate to the level of risk in action, is conducive to dealing with various risks including uncertainty risks and meets the needs of biotechnological risks governance, providing a strong theoretical guarantee for the balance between technological progress and social security development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.